NCT01390025View on ClinicalTrials.gov

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Influenza, Human
Interventions
BIOLOGICAL

TCN-032

TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.

BIOLOGICAL

Placebo

Placebo - 0.9% Sodium Chloride for Injection, USP

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Baltimore

All Listed Sponsors
lead

Theraclone Sciences, Inc.

INDUSTRY

NCT01390025 - Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza | Biotech Hunter | Biotech Hunter